دورية أكاديمية
أعرض في EDS

Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.

التفاصيل البيبلوغرافية
العنوان: Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
المؤلفون: Wald NJ; Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK. n.j.wald@qmul.ac.uk., Luteijn JM; Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK., Morris JK; Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK., Taylor D; UCL School of Pharmacy, BMA/Tavistock House, London, WC1H 9JP, UK., Oppenheimer P; Christ Church, Oxford, OX1 1DP, UK.
المصدر: European journal of epidemiology [Eur J Epidemiol] 2016 Apr; Vol. 31 (4), pp. 415-26. Date of Electronic Publication: 2016 Mar 05.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Kluwer Academic Publishers Country of Publication: Netherlands NLM ID: 8508062 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7284 (Electronic) Linking ISSN: 03932990 NLM ISO Abbreviation: Eur J Epidemiol Subsets: MEDLINE
أسماء مطبوعة: Publication: Dordrecht : Kluwer Academic Publishers
Original Publication: [Rome : The Journal, 1985-
مواضيع طبية MeSH: Cost-Benefit Analysis*, Amlodipine/*administration & dosage , Cardiovascular Agents/*administration & dosage , Hydrochlorothiazide/*administration & dosage , Losartan/*administration & dosage , Myocardial Infarction/*prevention & control , Simvastatin/*administration & dosage , Stroke/*prevention & control, Aged ; Aged, 80 and over ; Aspirin/therapeutic use ; Cardiovascular Agents/economics ; Case-Control Studies ; Cohort Studies ; Humans ; Markov Chains ; Middle Aged ; Myocardial Infarction/economics ; Polypharmacy ; Primary Prevention ; Quality-Adjusted Life Years ; Simvastatin/economics ; Stroke/economics ; United Kingdom
مستخلص: The primary prevention of cardiovascular disease is a public health priority. To assess the costs and benefits of a Polypill Prevention Programme using a daily 4-component polypill from age 50 in the UK, we determined the life years gained without a first myocardial infarction (MI) or stroke, together with the total service cost (or saving) and the net cost (or saving) per year of life gained without a first MI or stroke. This was estimated on the basis of a 50 % uptake and a previously published 83 % treatment adherence. The total years of life gained without a first MI or stroke in a mature programme is 990,000 each year in the UK. If the cost of the Polypill Prevention Programme were £1 per person per day, the total cost would be £4.76 bn and, given the savings (at 2014 prices) of £2.65 bn arising from the disease prevented, there would be a net cost of £2.11 bn representing a net cost per year of life gained without a first MI or stroke of £2120. The results are robust to sensitivity analyses. A national Polypill Prevention Programme would have a substantial effect in preventing MIs and strokes and be cost-effective.
References: BMJ. 2002 Jun 29;324(7353):1570-6. (PMID: 12089098)
Lancet. 2002 Dec 14;360(9349):1903-13. (PMID: 12493255)
BMJ. 2003 Jun 28;326(7404):1419. (PMID: 12829553)
BMJ. 2003 Jun 28;326(7404):1423. (PMID: 12829554)
BMJ. 2003 Jun 28;326(7404):1427. (PMID: 12829555)
J Public Health Med. 1992 Sep;14(3):250-6. (PMID: 1419202)
Health Technol Assess. 2003;7(31):1-94. (PMID: 14604498)
Circulation. 2005 Oct 11;112(15):2301-6. (PMID: 16216977)
Am J Cardiol. 2006 Apr 17;97(8A):52C-60C. (PMID: 16581329)
Heart. 2006 Oct;92(10):1384-9. (PMID: 16702172)
Lancet. 2006 Aug 19;368(9536):679-86. (PMID: 16920473)
Lancet. 2007 Dec 1;370(9602):1829-39. (PMID: 18061058)
Pharmacoeconomics. 2008;26(9):733-44. (PMID: 18767894)
Age Ageing. 2009 Jan;38(1):27-32. (PMID: 19141506)
BMJ. 2009 May 19;338:b1665. (PMID: 19454737)
Lancet. 2010 Feb 27;375(9716):735-42. (PMID: 20167359)
J Eval Clin Pract. 2012 Jun;18(3):612-5. (PMID: 21276141)
J Med Screen. 2011;18(1):1. (PMID: 21536808)
PLoS One. 2011 May 04;6(5):e18742. (PMID: 21573224)
BMJ Open. 2011 Jan 1;1(2):e000269. (PMID: 22021893)
BMJ Open. 2011 Dec 21;1(2):e000363. (PMID: 22189351)
BMJ. 2012 Jan 25;344:d8059. (PMID: 22279113)
PLoS One. 2012;7(7):e41297. (PMID: 22815989)
Int J Cardiol. 2013 Sep 30;168(2):934-45. (PMID: 23218570)
Eur J Epidemiol. 2014 Sep;29(9):605-12. (PMID: 25063437)
Eur J Epidemiol. 2015 Jun;30(6):521-3. (PMID: 26013360)
J Med Screen. 2016 Sep;23(3):115. (PMID: 26841798)
J Med Screen. 2017 Mar;24(1):50-53. (PMID: 27072544)
Rand Health Q. 2014 Mar 1;4(1):3. (PMID: 28083317)
فهرسة مساهمة: Keywords: Cardiovascular diseases; Cost–benefit analysis; Myocardial infarction; Polypill; Primary prevention; Stroke
المشرفين على المادة: 0 (Cardiovascular Agents)
0J48LPH2TH (Hydrochlorothiazide)
1J444QC288 (Amlodipine)
AGG2FN16EV (Simvastatin)
JMS50MPO89 (Losartan)
R16CO5Y76E (Aspirin)
تواريخ الأحداث: Date Created: 20160307 Date Completed: 20170908 Latest Revision: 20190111
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC4877433
DOI: 10.1007/s10654-016-0122-1
PMID: 26946426
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-7284
DOI:10.1007/s10654-016-0122-1